Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
This study is currently recruiting participants.
Verified December 2011
by Dana-Farber Cancer Institute
Study NCT01465334 Information provided by Dana-Farber Cancer Institute
First Received on October 18, 2011. Last Updated on February 20, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
CLL
SLL
Interventions listed in this trial
Ofatumumab
High-Dose Methylprednisolone
Alemtuzumab
Additional drug interventions recognized in this trial
Campath 1G
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
National Comprehensive Cancer Network
GlaxoSmithKline
Back to top of Main Content
